<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 20, 2000
ALGOS PHARMACEUTICAL CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-28844 22-3142274
---------------------------- --------- ----------
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification Number)
1333 Campus Parkway, Neptune, New Jersey 07753
----------------------------------------------
(Address of principal executive offices) (Zip Code)
(732) 938-5959
----------------------------------------------
(Registrants' telephone number, including area code)
N/A
----------------------------------------------
(former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
On June 20, 2000, Algos Pharmaceutical Corporation mailed a letter to
its stockholders clarifying certain matters with respect to the election to
receive non-transferable warrants, in lieu of the transferable warrants, in the
previously disclosed merger of Algos with Endo Inc., a wholly owned subsidiary
of Endo Pharmaceuticals Holdings Inc.
The election procedure is as set forth in the attached letter. Note that
Algos stockholders who do not complete all four steps outlined on the attached
letter will not be able to elect to receive non-transferable warrants in the
merger but will receive transferable, freely tradable warrants. Accordingly,
holders who have purchased shares of Algos common stock after May 19, 2000 and
prior to the completion of the merger will not be able to elect to receive non-
transferable warrants in the merger and will, therefore, receive transferable
warrants instead. The letter is attached as Exhibit 99.1 to this report.
The Exhibits hereto are incorporated by reference herein and form an
integral part hereof.
<PAGE>
Item 7. Financial Statements and Exhibits.
Exhibits.
99.1 Letter, dated June 20, 2000, to Algos stockholders from John W.
Lyle, President and Chief Executive Officer of Algos, regarding
the election to receive non-transferable warrants.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 20, 2000
ALGOS PHARMACEUTICAL CORPORATION
By: /s/ John W. Lyle
-----------------------------
John W. Lyle
President and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
Sequentially
Exhibit No. Numbered Page
----------- -------------
99.1 Letter, dated June 20, 2000, to Algos stockholders
from John W. Lyle, President and Chief Executive
Officer of Algos, regarding the election to receive
non-transferable warrants.
